Figure S7. Prevalence of Cyclin E1-P16INK4Ahigh tumors that express RB. A, Kaplan Meier curves based on CCNE1 status generated from The Cancer Genome Atlas (TCGA) serous ovarian carcinoma database. HR, hazard ratio; DFS, disease-free survival; OS, overall survival. Amp, amplification. B, Oncoprint of the serous ovarian carcinoma TCGA database for the indicated cell cycle genes. C, Normalized intensity for Cyclin D1, Cyclin E1, or P16INK4A expression within clusters 1, 3, and 4 (n = 82002 for cluster 1, n = 150037 for cluster 3, and n = 34088 for cluster 4; unpaired t-test between clusters 1 and 4). D, SCIMAP analysis of unique spatial single cell protein expression signatures of all 159 cores from the patient-derived gynecological tumor microarray (TMA). E, Computational algorithm-based identification of Cyclin E1high/P16high/RB+ cores from the gynecological TMA expected to be sensitive to CDK2 inhibition.